Characterisation and evaluation of pharmaceutical solvates of Atorvastatin calcium by thermoanalytical and spectroscopic studies

Chemistry Central Journal

Renu Chadha¹  Astha Kuhad¹  Poonam Arora¹  Shyam Kishor² 

[1] University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India

[2] Department of Chemistry, Janta Vedic (PG) College, Baraut, Meerut, Uttar Pradesh, India

关键词: 13C /MAS solid state NMR;    Calorimetry;    Heat capacity;    Recrystalliztion;    Solvate;   

Others  :  788062
DOI  :  10.1186/1752-153X-6-114

 received in 2012-03-28, accepted in 2012-09-28,  发布年份 2012

【 摘 要 】

Background

Atorvastatin calcium (ATC), an anti-lipid biopharmaceutical class II drug, is widely prescribed as a cholesterol-lowering agent and is presently the world’s best-selling medicine. A large number of crystalline forms of ATC have been published in patents. A variety of solid forms may give rise to different physical properties. Therefore, the discovery of new forms of this unusual molecule, ATC, may still provide an opportunity for further improvement of advantageous properties.

Results

In the present work, eight new solvates (Solvate I-VIII) have been discovered by recrystallization method. Thermal behaviour of ATC and its solvates studied by DSC and TGA indicate similar pattern suggesting similar mode of entrapment of solvent molecules. The type of solvent present in the crystal lattice of the solvates is identified by GC-MS analysis and the stoichiometric ratio of the solvents is confirmed by ¹HNMR. The high positive value of binding energy determined from thermochemical parameters indicates deep inclusion of the solvent molecules into the host cavity. The XRPD patterns point towards the differences in their crystallanity, however, after desolvation solvate II, III, IV, V and VIII transform to isostructral amorphous desolvated solvates. The order of crystallinity was confirmed by solution calorimetric technique as the enthalpy of solution is an indirect measure of lattice energy. All the solvates behaved endothermically following the order solvate-VIII (1-butanol solvate) < solvate-I (isoproplyate) < solvate-V (methanol solvate) < solvate-III (ethonalate) < solvate-VI (acetone ethanol solvate) < solvate-IV (t-butanol solvate) < solvate-II (THF solvate) < solvate-VII (mixed hemi-ethanol hydrate). The positive value of the heat capacity of the solvate formation provides information about the state of solvent molecules in the host lattice. The solvents molecules incorporated in the crystal lattice induced local chemical environment changes in the drug molecules which are observed in ¹³CP/MAS NMR spectral changes.

Conclusions

Aqueous solubility of solvate-VIII was found to be maximum, however, solvate-I and VIII showed better reduction in total cholesterol and triglyceride levels as compared to atorvastatin against triton-induced dyslipidemia.

【 授权许可】

   
2012 Chadha et al.; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Othman A, Evans JSO, Evans IR, Harris RK, Hodgkinson P: Structural study of polymorphs and solvates of finasteride. J Pharm Sci 2007, 96:1380-1397.
• [2]Griesser UJ: The importance of solvates. In Polymorphism in the Pharmaceutical Industry. Edited by Hilfiker R. Weinheim, Germany: Viley-Vch Verlag GmbH & Co. KGaA; 2006:211-233.
• [3]Rustichellia C, Gamberini G, Feriolia V, Gamberinia MC, Ficarrab R, Tommasinic S: Solid state study of polymorphic drug: carbamazepine. J Pharm Biomed Anal 2000, 23:41-54.
• [4]Tonder CV, Mahlatji MD, Malan SF, Liebenberg , Caira MR, Song M, Villiers MMD: Preparation and physicochemical characterization of 5 niclosamide solvates and 1 hemisolvate. AAPS Pharm Sci Tech 2004, 5:Article 12.
• [5]Chadha R, Arora P, Saini A, Singla ML, Jain DVS: Characterization of solvatomorphs of methotrexate using thermoanalytical and other techniques. Acta Pharm 2009, 59:245-247.
• [6]Jin YS, Ulrich J: New Crystalline Solvates of Atorvastatin Calcium. Chem Eng Tech 2010, 33(5):839-44.
• [7]Grünenberg A: Solid form analysis with special consideration of perfusion calorimetry PhD thesis. Polymorphie und thermische Analyse pharmazeutischer Wirkstoffe. Pharmazie in unserer Zeit; 1997.
• [8]SohnY T: Effect of crystal form on bioavailability. J Korean Pharm Sci 2004, 34:443-452.
• [9]Sohn YT: Crystal forms of an angiotensin II receptor antagonist BR-A657. J Therm Anal Calori 2007, 89:799-802.
• [10]SohnY T, Lee YH: Polymorphism of doxazosin mesylate. Arch Pharm Res 2005, 28:730-735.
• [11]Khankari RK, Grant DJW: Pharmaceutical hydrates. Thermochimica Acta 1995, 24E:61-79.
• [12]Ghugare P, Dongre V, Karmuse P: Structural Study of Polymorphs and Solvates of Finasteride. J Pharm Biomed Anal 2009, 51:532-540.
• [13]Shete G, Puri V, Bansal AK: Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples. AAPS PharmSciTech 2010, 11:598-609.
• [14]Henwood SQ, Liebenberg W, Lourens R, Villiers M: Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates and hydrates. Drug Devel Ind Pharm 2001, 27:1017-1030.
• [15]Ghugaree P, Dongre V, Karmuse P, Rana R, Singh D, Kumar A, Filmwala Z: Solid-state investigation and characterization of the polymorphic and pseudopolymorphic forms of indpamide. J Pharm Biomed Anal 2009, 51:532-540.
• [16]Caira MR, Bettinetti G, Sorrenti M, Catenacci L: Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of Brodimoprim. J Pharm Sci 2007, 96:996-1007.
• [17]Masuda K, Tabata S, Kono H, Sakata Y, Hayase T, Yonemochi E, Terada K: Solid-state 13C NMR study of indomethacin polymorphism. Int J Pharmaceutics 2006, 318:146-153.
• [18]Park JS, Kang SJ, Kim CK: Use of CP/MAS solid-state NMR for the characterization of solvate molecules within estradiol crystal forms. E J Pharmaceutics and Biopharmaceutics 2005, 60:407-412.
• [19]Stephenson GA, Stowell JG, Toms PH, Dorman DE, Greene JR, Byrn SR: Solid-state Analysis of polymorphic, isomorphic, and solvated forms of dirithromycin. J Am Chem Soc 1994, 116:5766-5773.
• [20]Stephenson GA, Stowell JG, Toms PH, Pfeiffer RR, Byrn SR: Solid-state investigations of erythromycin A dehydrate: structure, NMR spectroscopy, and hygroscopy. J Pharm Sci 1997, 86:1239-1244.
• [21]Caira MR, Bettinetti G, Sorrenti M: Structural relationships, thermal properties and physicochemical characterization of anhydrous and solvated crystalline forms of tetroxoprim. J Pharm Sci 2002, 91:467-481.
• [22]Guideline for Residual Solvents: International Conference on Harmonization of Technical Requirements for registration of Pharmaceuticals for Human Use, ICH Q3 impurites. Geneva, Switzerland; July 1997. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf webcite